165 related articles for article (PubMed ID: 9854503)
21. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine.
Hamajima K; Hoshino Y; Xin KQ; Hayashi F; Tadokoro K; Okuda K
Clin Immunol; 2002 Jan; 102(1):12-8. PubMed ID: 11781062
[TBL] [Abstract][Full Text] [Related]
22. Prime-boost strategies in DNA vaccines.
Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
[TBL] [Abstract][Full Text] [Related]
23. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
24. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
25. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
[TBL] [Abstract][Full Text] [Related]
26. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
27. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
[TBL] [Abstract][Full Text] [Related]
28. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
[TBL] [Abstract][Full Text] [Related]
29. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
[TBL] [Abstract][Full Text] [Related]
30. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
[TBL] [Abstract][Full Text] [Related]
31. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
32. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity.
Xin KQ; Lu Y; Hamajima K; Fukushima J; Yang J; Inamura K; Okuda K
Clin Immunol; 1999 Jul; 92(1):90-6. PubMed ID: 10413656
[TBL] [Abstract][Full Text] [Related]
33. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
34. Novel adjuvants for B cell immune responses.
Loré K; Karlsson Hedestam GB
Curr Opin HIV AIDS; 2009 Sep; 4(5):441-6. PubMed ID: 20048709
[TBL] [Abstract][Full Text] [Related]
35. Antigen presentation and related immunological aspects of HIV-1 vaccines.
Steinman RM; Germain RN
AIDS; 1998; 12 Suppl A():S97-112. PubMed ID: 9632991
[No Abstract] [Full Text] [Related]
36. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system.
Ara Y; Saito T; Takagi T; Hagiwara E; Miyagi Y; Sugiyama M; Kawamoto S; Ishii N; Yoshida T; Hanashi D; Koshino T; Okada H; Okuda K
Immunology; 2001 May; 103(1):98-105. PubMed ID: 11380697
[TBL] [Abstract][Full Text] [Related]
37. Development of a multicomponent candidate vaccine for HIV-1.
Kim JJ; Ayyavoo V; Bagarazzi ML; Chattergoon M; Boyer JD; Wang B; Weiner DB
Vaccine; 1997 Jun; 15(8):879-83. PubMed ID: 9234538
[TBL] [Abstract][Full Text] [Related]
38. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody.
Toda S; Ishii N; Okada E; Kusakabe KI; Arai H; Hamajima K; Gorai I; Nishioka K; Okuda K
Immunology; 1997 Sep; 92(1):111-7. PubMed ID: 9370932
[TBL] [Abstract][Full Text] [Related]
39. HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.
Tsuji T; Fukushima J; Hamajima K; Ishii N; Aoki I; Bukawa H; Ishigatsubo Y; Tani K; Okubo T; Dorf ME; Okuda K
Immunology; 1997 Jan; 90(1):1-6. PubMed ID: 9038705
[TBL] [Abstract][Full Text] [Related]
40. Modulating the immune response to genetic immunization.
Cohen AD; Boyer JD; Weiner DB
FASEB J; 1998 Dec; 12(15):1611-26. PubMed ID: 9837851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
